

JUN 19 2000

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: P-IX 2947	
SERIAL NO: 09/203,768	FILING DATE: December 2, 1998	EXAMINER: L. Helms	GROUP ART UNIT: 1642	
INVENTION: TUMOR SPECIFIC HUMAN MONOCLONAL ANTIBODIES AND METHODS OF USE				

RECEIVED

JUN 23 2000

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on May 31, 2000.

By: David A. Gay
David A. Gay, Reg. No.: 39,200

May 31, 2000
Date of Signature

Transmitted herewith is an amendment in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☒ Sequence Listing pages 1-7 along with diskette.
- ☒ Statement under 37 C.F.R. § 1.821(f) and (g).
- ☒ Petition for Extension of Time is enclosed.
- ☐ Request for Continued Examination is enclosed.
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	46	- 46	- 0	x	\$9	\$18	= \$0.00	\$0.00
INDEPENDENT CLAIMS	14	- 14	- 0	x	\$39	\$78	= \$0.00	\$0.00
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		____ YES	____ X ____ NO		\$130	\$260	= \$0.00	\$0.00
					TOTAL ADDITIONAL FEE		\$0.00	\$0.00

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Inventors: Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
Page 2

— Please charge my Deposit Account No. 03-0370 the amount of \$_____. A duplicate copy of this sheet is enclosed.

X A check in the amount of \$435.00 is enclosed which covers the fee for a three-month extension of time.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

X Any additional filing fees required under 37 C.F.R. 1.16.

X Any patent application processing fees under 37 C.F.R. 1.17.

X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



David A. Gay
Registration No.: 39,200
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001

USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-IX 2947

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9a
chh
629-00

In re Application of)
Watkins and Huse)
Serial No: 09/203,768)
Filed: December 2, 1998)
For: TUMOR SPECIFIC HUMAN)
MONOCLONAL ANTIBODIES)
AND METHODS OF USE)

Group Art Unit: 1642

Examiner: L. Helms

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C.
20231, on May 31, 2000

By David A. Gay
David A. Gay, Reg. No. 35,200

Commissioner for Patents
Washington, D.C. 20231

May 31, 2000
Date of Signature

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed
February 3, 2000, entry of the following Amendments and Remarks
is respectfully requested. A response to the Office Action was
originally due March 4, 2000. Applicants submit herewith a
Petition of Extension of Time to extend the time to reply to the
Office Action for 3 months, until June 4, 2000. Accordingly,
this Response is being timely filed.

REMARKS

Claims 1-46 are pending in the above-identified
application and are subject to a restriction requirement under 35
U.S.C. § 121. The Office Action alleges that the claims are
directed to sixteen independent inventions set forth as follows: